Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol + Adebrelimab + Chemotherapy in SCLC
NCT07886047Phase 1Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- May 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of propranolol in small cell lung cancer (SCLC) (2 cohorts), sponsored by The Second Xiangya Hospital. Primary endpoints: Objective Response Rate at 24 months, Disease Control Rate at 24 months and 3 more. Started May 2026; status: recruiting.
02
Drugs
propranolol
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07886047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07886047.